Journal Scans
Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
Casopitant Is Beneficial for Chemotherapy-Related Nausea and Vomiting
J Herrstedt, W Apornwirat, A Shaharyar, Z Aziz, F Roila, S Van Belle, MW Russo, J Levin, S Ranganathan, M Guckert, SM Grunberg
20090905
2009 Oct 5
J Clin Oncol
Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
J Clin Oncol. 2009 Oct 5; Epub ahead of print, J Herrstedt, W Apornwirat, A Shaharyar, Z Aziz, F Roila, S Van Belle, MW Russo, J Levin, S Ranganathan, M Guckert, SM Grunberg
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Chemotherapy-induced nausea and vomiting (CINV) may result in low adherence to, and possible withdrawal from, beneficial chemotherapy. Prevention of CINV during the first chemotherapy cycle may reduce the chance of its presentation in subsequent treatment cycles. Inhibition of the serotonin/5-hydroxytryptamine receptor 3 (5-HT3) and of the substance P/neurokinin-1 (NK-1) receptors are important mechanisms of antiemesis. In phase II studies, the novel NK-1 receptor agonist casopitant had demonstrated...
